Protective role of Ca<sup>2+</sup>-permeable TRPV6 in dextran sulfate sodium-induced colitis in mice

  • Mori Fuho
    Div. Pathol. Sci., Dept. Pharmacol. Exp. Ther., Kyoto Pharm. Univ.
  • Takayama Mayu
    Div. Pathol. Sci., Dept. Pharmacol. Exp. Ther., Kyoto Pharm. Univ.
  • Saito Michiko
    BIo-Sci. Res. Ctr., Kyoto Pharm. Univ.
  • Yasuda Hiroyuki
    Div. Pathol. Sci., Dept. Pharmacol. Exp. Ther., Kyoto Pharm. Univ.
  • Matsumoto Kenjiro
    Div. Pathol. Sci., Dept. Pharmacol. Exp. Ther., Kyoto Pharm. Univ.
  • Kato Shinichi
    Div. Pathol. Sci., Dept. Pharmacol. Exp. Ther., Kyoto Pharm. Univ.

Bibliographic Information

Other Title
  • Ca<sup>2+</sup>高選択性TRPV6のデキストラン硫酸ナトリウム誘起マウス大腸炎の病態における役割

Abstract

<p>Transient receptor potential vanilloid 6 (TRPV6), which is a highly Ca2+-selective ion channel, is expressed in gastrointestinal epithelium and implicated in maintaining Ca2+ homeostasis via transcellular Ca2+ transport. However, the local pathophysiological roles of TRPV6 in the gastrointestinal tract remains undefined. In the current study, we investigated the role of TRPV6 in the pathogenesis of experimentally-induced colitis in mice. TRPV6-deficient (TRPV6KO) mice were generated by CRISPR-Cas9-mediated genome editing on C57BL/6 background. Experimental colitis was induced in TRPV6KO and wild-type (WT) mice by the treatment with dextran sulfate sodium (DSS) for 7 days. Intestinal permeability was evaluated by FITC-dextran methods. DSS treatment produced body weight loss with diarrhea and blood feces, and severe colitis characterized by shortening colon length and histological injury 7 days later. The severity of colitis with systemic symptoms was significantly augmented in TRPV6KO mice compared with WT mice. Intestinal permeability was increased in TRPV6KO compared with WT mice. The expression of E-cadherin and occludin in the colon was reduced in TRPV6KO mice compared with WT mice. These findings suggest that TRPV6 plays a protective role in the pathogenesis of DSS-induced colitis via maintaining colonic barrier functions. Thus, TRPV6 may be a novel target for the treatment of gastrointestinal diseases.</p>

Journal

Details 詳細情報について

Report a problem

Back to top